$MBRX
Moleculin Biotech, Inc.

2023 Q4 Form 10-Q Financial Statement

#000143774923031391 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.252M $2.640M $2.838M
YoY Change -20.65% -14.48% 42.47%
% of Gross Profit
Research & Development $6.632M $3.280M $4.178M
YoY Change 58.74% -45.01% 31.42%
% of Gross Profit
Depreciation & Amortization $37.00K $32.00K $32.00K
YoY Change 15.63% 0.0% -5.88%
% of Gross Profit
Operating Expenses $8.919M $5.947M $7.048M
YoY Change 26.55% -34.53% 35.41%
Operating Profit -$5.947M
YoY Change -34.53%
Interest Expense -$858.0K $324.0K $277.0K
YoY Change -409.75% -28.63% -88.31%
% of Operating Profit
Other Income/Expense, Net $18.00K $13.00K $1.000K
YoY Change 1700.0% -31.58% -90.0%
Pretax Income -$10.27M -$5.610M -$6.770M
YoY Change 51.68% -34.85% 139.65%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$10.27M -$5.609M -$6.770M
YoY Change 51.68% -34.86% 139.65%
Net Earnings / Revenue
Basic Earnings Per Share -$0.19
Diluted Earnings Per Share -$5.09 -$0.19 -$0.24
COMMON SHARES
Basic Shares Outstanding 29.81M 29.81M 28.63M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $23.55M $24.58M $43.15M
YoY Change -45.42% -51.22% -39.15%
Cash & Equivalents $23.55M $24.60M $43.10M
Short-Term Investments
Other Short-Term Assets $1.204M $3.020M $1.403M
YoY Change -14.18% 72.47% -11.98%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $26.27M $27.60M $45.60M
YoY Change -42.38% -48.4% -37.11%
LONG-TERM ASSETS
Property, Plant & Equipment $272.0K $225.0K $275.0K
YoY Change -1.09% -26.47% -18.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $11.94M $11.92M $11.83M
YoY Change 1.0% 0.35% 2.01%
TOTAL ASSETS
Total Short-Term Assets $26.27M $27.60M $45.60M
Total Long-Term Assets $11.94M $11.92M $11.83M
Total Assets $38.22M $39.52M $57.42M
YoY Change -33.45% -39.54% -31.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.498M $2.008M $2.095M
YoY Change 19.24% -43.72% 53.59%
Accrued Expenses $4.317M $1.880M $2.724M
YoY Change 58.48% -32.71% 20.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.815M $3.888M $4.819M
YoY Change 41.42% -38.89% 33.05%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.329M $500.0K $412.0K
YoY Change 1193.45% -15.68% -72.07%
Total Long-Term Liabilities $5.329M $500.0K $412.0K
YoY Change 1193.45% -15.68% -72.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.815M $3.888M $4.819M
Total Long-Term Liabilities $5.329M $500.0K $412.0K
Total Liabilities $12.14M $4.385M $5.231M
YoY Change 132.15% -36.95% 2.63%
SHAREHOLDERS EQUITY
Retained Earnings -$131.6M -$121.3M -$101.8M
YoY Change 29.27% 27.55% 39.82%
Common Stock $157.7M $156.5M $154.0M
YoY Change 2.38% 1.95% 1.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.07M $35.14M $52.19M
YoY Change
Total Liabilities & Shareholders Equity $38.22M $39.52M $57.42M
YoY Change -33.45% -39.54% -31.71%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q4
OPERATING ACTIVITIES
Net Income -$10.27M -$5.609M -$6.770M
YoY Change 51.68% -34.86% 139.65%
Depreciation, Depletion And Amortization $37.00K $32.00K $32.00K
YoY Change 15.63% 0.0% -5.88%
Cash From Operating Activities -$5.411M -$7.550M -$7.256M
YoY Change -25.43% -0.36% 70.41%
INVESTING ACTIVITIES
Capital Expenditures $84.00K $20.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$84.00K -$20.00K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.461M 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -5.411M -7.550M -7.256M
Cash From Investing Activities -84.00K -20.00K 0.000
Cash From Financing Activities 4.461M 0.000 0.000
Net Change In Cash -1.034M -7.570M -7.256M
YoY Change -85.75% -0.24% 69.65%
FREE CASH FLOW
Cash From Operating Activities -$5.411M -$7.550M -$7.256M
Capital Expenditures $84.00K $20.00K $0.00
Free Cash Flow -$5.495M -$7.570M -$7.256M
YoY Change -24.27% -0.09% 71.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29810443
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29810443
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28627827
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28627827
CY2023Q2 mbrx Number Of Core Drug Technologies
NumberOfCoreDrugTechnologies
3 pure
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
12000 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37758
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4671997
dei Entity Address Address Line1
EntityAddressAddressLine1
5300 Memorial Drive, Suite 950
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77007
dei City Area Code
CityAreaCode
713
dei Local Phone Number
LocalPhoneNumber
300-5160
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
MBRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29810443
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24579000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43145000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3024000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2451000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
27603000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
45596000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
225000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
275000 usd
CY2023Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 usd
CY2022Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
547000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
403000 usd
CY2023Q3 us-gaap Assets
Assets
39523000 usd
CY2022Q4 us-gaap Assets
Assets
57422000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2008000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2095000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1880000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2724000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3888000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4819000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
496000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
335000 usd
CY2023Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1000 usd
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
77000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
4385000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
5231000 usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
30000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
29000 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
156446000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
153985000 usd
CY2023Q3 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
-3000 usd
CY2022Q4 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
12000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121335000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101835000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
35138000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
52191000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39523000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57422000 usd
CY2023Q3 us-gaap Revenues
Revenues
0 usd
CY2022Q3 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3280000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5965000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12855000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14790000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2635000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3087000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7765000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8704000 usd
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
32000 usd
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
32000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
92000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
98000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
5947000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
9084000 usd
us-gaap Operating Expenses
OperatingExpenses
20712000 usd
us-gaap Operating Expenses
OperatingExpenses
23592000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5947000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9084000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-20712000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-23592000 usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1000 usd
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-421000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-76000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1184000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
19000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
30000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
39000 usd
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
324000 usd
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
33000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1106000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
114000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5609000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8611000 usd
us-gaap Net Income Loss
NetIncomeLoss
-19500000 usd
us-gaap Net Income Loss
NetIncomeLoss
-22255000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.3
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29809236
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28627610
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29419904
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28596501
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5609000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8611000 usd
us-gaap Net Income Loss
NetIncomeLoss
-19500000 usd
us-gaap Net Income Loss
NetIncomeLoss
-22255000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-10000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-19000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-15000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-38000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5619000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8630000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19515000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22293000 usd
us-gaap Net Income Loss
NetIncomeLoss
-19500000 usd
us-gaap Net Income Loss
NetIncomeLoss
-22255000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
92000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
98000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1505000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1740000 usd
mbrx Common Stock Issued For Licence Rights Under License Agreement
CommonStockIssuedForLicenceRightsUnderLicenseAgreement
772000 usd
mbrx Common Stock Issued For Licence Rights Under License Agreement
CommonStockIssuedForLicenceRightsUnderLicenseAgreement
0 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-76000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1184000 usd
mbrx Operating Lease Noncash Expense Net
OperatingLeaseNoncashExpenseNet
105000 usd
mbrx Operating Lease Noncash Expense Net
OperatingLeaseNoncashExpenseNet
96000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
573000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1507000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-87000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2204000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-932000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
425000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18694000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20383000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
43000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-43000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-67000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
25000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
23000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
211000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
186000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-23000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-15000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-38000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18566000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20511000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43145000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70903000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24579000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50392000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
52191000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
141000 usd
CY2023Q1 mbrx Stock Issued During Period Value License Rights
StockIssuedDuringPeriodValueLicenseRights
772000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
499000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7915000 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-4000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
45684000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
69000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-21000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
513000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5976000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
40268000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-4000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
493000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5609000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-10000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
35138000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
78993000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
527000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6867000 usd
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
12000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
72665000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-12000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
514000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-6777000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-31000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
66359000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-11000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
699000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8611000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-19000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
58417000 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">1.</em> Nature of Business </b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The terms "MBI" or "the Company", "we", "our", and "us" are used herein to refer to Moleculin Biotech, Inc. MBI is a Phase <em style="font: inherit;">2</em> clinical-stage pharmaceutical company, organized as a Delaware corporation in <em style="font: inherit;"> July 2015, </em>with clinical programs for hard-to-treat cancers and viruses. The Company has <span style="-sec-ix-hidden:c104884362">three</span> core technologies, each of which have had <em style="font: inherit;">one</em> or more drugs successfully complete a Phase <em style="font: inherit;">1</em> clinical trial, based substantially on discoveries made at and licensed from The University of Texas System on behalf of the MD Anderson Cancer Center (MD Anderson) in Houston, Texas. The Company has <em style="font: inherit;">two</em> wholly owned subsidiaries, Moleculin Australia Pty. Ltd., which was set up to perform certain preclinical development and Moleculin Amsterdam B.V., which acts as its legal representative for clinical trials in Europe. The Company utilizes its own internal resources and funds to conduct some of these trials and also has trials being conducted via physician-sponsored trials. The physician-sponsored trials utilize primarily external funds, such as grant funds, which are <em style="font: inherit;">not</em> presented in these financial statements. The Company does <em style="font: inherit;">not</em> have manufacturing facilities and all manufacturing activities are contracted out to <em style="font: inherit;">third</em> parties. Additionally, the Company does <em style="font: inherit;">not</em> have a sales organization. The Company’s overall strategy is to seek potential out-licensing or outsourcing opportunities with development/commercialization strategic partners who are better suited for the marketing, sales and distrib<span style="background-color:#ffffff;">ution of its drugs, if approved.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><span style="background-color:#ffffff;">On <em style="font: inherit;"> May 5, 2023, </em>the Company received a letter from the Nasdaq Capital Market (Nasdaq) notifying the Company that for the prior <em style="font: inherit;">30</em> consecutive business days the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on Nasdaq pursuant to Nasdaq Listing Rule <em style="font: inherit;">5550</em>(a)(<em style="font: inherit;">2</em>) (the "Bid Price Rule"). The deficiency letter did <em style="font: inherit;">not</em> result in the immediate delisting of the Company's common stock from the Nasdaq. In accordance with Nasdaq Listing Rule <em style="font: inherit;">5810</em>(c)(<em style="font: inherit;">3</em>)(A), the Company was  provided an initial period of <em style="font: inherit;">180</em> calendar days, until <em style="font: inherit;"> November 1, 2023, </em>to regain compliance with the Bid Price Rule. In addition, the Company was required to notify Nasdaq of its intent to cure the minimum bid price deficiency, which <em style="font: inherit;"> may </em>include, if necessary, implementing a reverse stock split. </span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><span style="background-color:#ffffff;">On <em style="font: inherit;"> November 2, </em><em style="font: inherit;">2023,</em> the Company received a 180-calendar day extension, until <em style="font: inherit;"> April 29, 2024, </em>from the Nasdaq to regain compliance with Bid Price Rule. The Company will continue to monitor the closing bid price of its common stock and plans to pursue available options to regain compliance with the Bid Price Rule, including potentially the Company’s Board of Directors authorizing a reverse stock split, as discussed further below. If the Company authorizes a reverse stock split, it will plan to effectuate the split <em style="font: inherit;">no</em> later than <em style="font: inherit;">ten</em> business days prior to the end of the extension in order to timely regain compliance. If, at any time before <em style="font: inherit;"> April 29, 2024, </em>the bid price for the Company's common stock closes at $1.00 or more for a minimum of <em style="font: inherit;">10</em> consecutive business days, the Nasdaq Staff will provide written notification to the Company that it complies with the Bid Price Rule, unless the Staff exercises its discretion to extend this <em style="font: inherit;">10</em> day period pursuant to Nasdaq Listing Rule <em style="font: inherit;">5810</em>(c)(<em style="font: inherit;">3</em>)(G).</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><span style="background-color:#ffffff;">On <em style="font: inherit;"> October 3, 2023, </em>the Company held a Special Meeting of Stockholders (the "Special Meeting"). The Company's stockholders granted the Board of Directors the authority to effect an amendment to the Company’s amended and restated certificate of incorporation to effect a reverse stock split of the outstanding shares of the Company’s common stock, at a reverse stock split ratio of between <em style="font: inherit;">1</em>-for-5 and <em style="font: inherit;">1</em>-for-20 as determined by the Board in its sole discretion, prior to the <em style="font: inherit;">one</em>-year anniversary of the Special Meeting. The Board of Directors has taken <em style="font: inherit;">no</em> action with regard to this matter.</span></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><span style="background-color:#ffffff;">If the Company does <em style="font: inherit;">not</em> regain compliance with the Bid Price Rule by <em style="font: inherit;"> April 29, 2024, </em>the Nasdaq Staff will provide written notification to the Company that its common stock <em style="font: inherit;"> may </em>be delisted. The Company would then be entitled to appeal the Nasdaq Staff’s determination to a NASDAQ Listing Qualifications Panel and request a hearing. There can be <em style="font: inherit;">no</em> assurance that, if the Company does appeal a delisting determination by the Nasdaq Staff to the NASDAQ Listing Qualifications Panel, that such appeal would be successful. There can be <em style="font: inherit;">no</em> assurance that the Company will be able to regain compliance with the Bid Price Rule. </span></p>
CY2023Q2 mbrx Nasdaq Compliance Minimum Closing Bid Price Per Share
NASDAQComplianceMinimumClosingBidPricePerShare
1
CY2023Q2 mbrx Nasdaq Compliance Extension Period
NASDAQComplianceExtensionPeriod
P180D
CY2023Q2 mbrx Nasdaq Compliance Minimum Closing Bid Price Per Share
NASDAQComplianceMinimumClosingBidPricePerShare
1
us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
134933
CY2022Q3 mbrx License Agreements Expense
LicenseAgreementsExpense
315000 usd
mbrx License Agreements Expense
LicenseAgreementsExpense
552000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><b>Use of Estimates -</b> The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors <em style="font: inherit;"> may </em>affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often <em style="font: inherit;"> may </em>yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process <em style="font: inherit;"> may </em>result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes. </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p>
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121300000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24600000 usd
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8500000
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5200000
us-gaap Operating Lease Payments
OperatingLeasePayments
91000 usd
CY2023Q3 mbrx License Agreements Expense
LicenseAgreementsExpense
221000 usd
CY2023Q3 mbrx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
735000 usd
CY2022Q4 mbrx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1337000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
549000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
437000 usd
CY2023Q3 mbrx Accrued Legal Regulatory Professional And Other Current
AccruedLegalRegulatoryProfessionalAndOtherCurrent
443000 usd
CY2022Q4 mbrx Accrued Legal Regulatory Professional And Other Current
AccruedLegalRegulatoryProfessionalAndOtherCurrent
748000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
88000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
116000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1880000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2724000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
493000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
699000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1505000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1740000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1496000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.49
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.6
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
34000 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
33000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
99000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
91000 usd
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
5000 usd
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
7000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
19000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
22000 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
39000 usd
CY2022Q3 us-gaap Lease Cost
LeaseCost
40000 usd
us-gaap Lease Cost
LeaseCost
118000 usd
us-gaap Lease Cost
LeaseCost
113000 usd
CY2023Q3 mbrx Operating Lease Monthly Rent Payment
OperatingLeaseMonthlyRentPayment
4700 usd
CY2023Q3 mbrx Operating Lease Rent Expense Annual Increase In Rent Percent
OperatingLeaseRentExpenseAnnualIncreaseInRentPercent
0.02 pure
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
12000 usd
us-gaap Sublease Income
SubleaseIncome
37000 usd
us-gaap Sublease Income
SubleaseIncome
32000 usd
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
34000 usd
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
21000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
109000 usd
mbrx License Agreements Expense
LicenseAgreementsExpense
815000 usd

Files In Submission

Name View Source Status
0001437749-23-031391-index-headers.html Edgar Link pending
0001437749-23-031391-index.html Edgar Link pending
0001437749-23-031391.txt Edgar Link pending
0001437749-23-031391-xbrl.zip Edgar Link pending
ex_560448.htm Edgar Link pending
ex_560449.htm Edgar Link pending
ex_560450.htm Edgar Link pending
ex_560451.htm Edgar Link pending
ex_593048.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
mbrx-20230930.xsd Edgar Link pending
mbrx20230930_10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
moleculinnewlogoresized.jpg Edgar Link pending
R1.htm Edgar Link pending
mbrx-20230930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
mbrx-20230930_lab.xml Edgar Link unprocessable
mbrx-20230930_pre.xml Edgar Link unprocessable
mbrx-20230930_def.xml Edgar Link unprocessable
mbrx20230930_10q_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending